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Drug approval is based on exposure, response, and variability 
of studied populations, typically excluding comorbidities/
medications and very ill patients, thus not representing real-
world populations. This results in wide variability in therapeutic 
outcome for individual patients. Model-informed precision dosing 
(MIPD) can characterize/quantify this variability, support optimal 
dose selection, and enable individualized therapy. The aim of this 
perspective is to raise awareness for MIPD, identify challenges 
hindering its implementation in clinical practice, provide 
recommendations, and highlight opportunities.
MIPD aims at tailoring doses to patients’ 
needs, and therefore presents a promising 
tool to increase treatment success.1 Within 
a Bayesian framework, typically prior 
knowledge about drug pharmacokinetics 
(PK) and exposure-response relationships 
are individualized based on individual 
patient characteristics (“covariates,” e.g., 
age, weight, sex, disease characteristics, or 
comedication) and PK or biomarker data 
to obtain individual model parameters 
(maximum a-posteriori estimates). Recently, 
Bayesian data assimilation methods have 
come into focus, overcoming major lim-
itations of maximum a posteriori-based 
approaches by enabling accurate uncer-
tainty quantification and propagation.2 In 
contrast to traditional and well-established 
therapeutic drug/biomarker monitoring 
(TDM), MIPD provides quantitative deci-
sion support to healthcare professionals for 
real-world patient populations integrating 
multi-level data. With the increase in 
available computing power,3 further meth-
odological advances enabling a com-
prehensive uncertainty quantification,2 
numerous publications demonstrating the 
clinical benefits of MIPD,4 and also the 
user-friendliness of few already existing 
MIPD tools,5 the question arises as to why 
the implementation of MIPD in clinical 
practice—with the exception of local ini-
tiatives at academic hospital centers6—still 
largely fails. In the following, we summarize 
selected key challenges that need to be ad-
dressed, and further perspectives beyond 
(see also Figure 1, Table 1). We propose 
an alignment for terminology and across 
scientific disciplines, thus enabling collab-
orative work. Furthermore, we provide a 
comprehensive literature overview of cur-
rent applications, review articles, innova-
tive methodology, initiatives, and already 
available software tools (Table S1).
DEFINITION/TERMINOLOGY
MIPD is a rapidly evolving research area in 
which multiple scientific disciplines/com-
munities and other stakeholders meet. Due 
to the diverse origins of MIPD research 
projects or MIPD tools, various terms exist 
in the literature for these approaches and 
methodologies (Table 1). As a result, terms 
and labels are used interchangeably, and al-
though there are many common features, 
various MIPD initiatives exist in parallel 
without touch points. Harmonization of 
the definitions across different therapeutic 
areas and scientific disciplines is therefore 
crucial.7 Following the successful example 
of “model-informed drug discovery and 
development” a joint effort and unified 
appearance under the consensus term 
“MIPD” will ensure greater visibility 
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and extension of the target audience to 
facilitate and accelerate implementation 
of MIPD in drug development and clin-
ical practice. Complementary to this, 
MIPD must be recognized as a collabo-
rative effort between different scientific 
disciplines, which ought to be leveraged 
in research projects investigating and de-
veloping MIPD approaches/tools. Only 
through collaborative efforts, MIPD can 
be realized and will become a clinical re-
ality. Moreover, the term “precision medi-
cine” also comprises other approaches (e.g., 
pharmacogenomics), which are often seen 
as unconnected with MIPD, at times even 
competing concepts in scientific discourse 
and clinical practice, whereas they should 
rather be understood as complementary 
approaches to take full advantage of them. 
MIPD offers the potential to serve as a 
platform simultaneously integrating vari-
ous approaches for therapy individualiza-
tion and optimization.4
UNDERSTANDING THE VALUE OF 
MIPD IN RESEARCH SETTINGS AND 
ROUTINE CLINICAL CARE
A major obstacle is still constituted by the 
fact that current curricula for physicians, 
clinical pharmacists, and other healthcare 
professionals are lacking in-depth train-
ing in quantitative pharmacology, which 
is needed to enable understanding, appli-
cation, and evaluation of MIPD concepts 
and tools. This needs to be addressed via 
increasing awareness (e.g., by publishing 
good examples and “best practices” in the 
right journals,7 and presenting at confer-
ences and workshops) and education (offer 
more training opportunities to acquire 
knowledge and expertise in model-in-
formed/quantitative approaches). User-
friendly software and integration into 
clinical workflow are ultimately needed to 
remove the remaining barriers and unleash 
the full power of MIPD tools. Healthcare 
professionals involved in drug treatment 
need to understand that “one-dose-fits-all” 
must be replaced by MIPD for the individ-
ual patient to improve therapy outcome. 
An MIPD tool will offer decision support, 
but the decision about the individual ther-
apy still rests with the treating physician 
or clinical pharmacist, who integrates the 
overall status of the patients. Additionally, 
current regulatory (e.g., registration of 
MIPD tools as medical devices) and 
healthcare system (e.g., reimbursement 
framework) level barriers further discour-
age the application of MIPD in clinical 
routine. Joint efforts among the scientific 
community promoting MIPD, healthcare 
professionals, pharmaceutical companies, 
and stakeholders in the regulatory/health-
care system environment are required.
SCIENTIFIC ASPECTS
MIPD provides opportunities for various 
approved and investigational drugs, how-
ever, not all drug therapies might benefit. 
Drugs with high associated treatment 
costs, potential severe adverse drug reac-
tions or a narrow therapeutic index, and/
or associated high interindividual variabil-
ity, are particularly qualified for precision 
dosing. However, there must be a reliable 
correlation between the drug or surrogate 
biomarker concentration (preferably in a 
readily available matrix) and the clinical 
effect. In addition, robust therapeutic PK, 
pharmacodynamic, or PK/pharmacody-
namic targets, utility functions, or target 
ranges must be established and thoroughly 
evaluated, which warrant large-scale clin-
ical trials and observational studies in 
“real-world” populations, if not yet es-
tablished during drug development. This 
can be particularly challenging for drugs 
with delayed (un-)desired effect (e.g., che-
motherapy), for which drug tolerance is 
Figure 1 Key challenges and perspectives for model-informed precision dosing (MIPD). PBPK, physiologically-based pharmacokinetics; PD, 
pharmacodynamics; PGx, pharmacogenomics; PK, pharmacokinetics; QSP, quantitative systems pharmacology; SmPC, summary of product 
characteristics.
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often developed (e.g., depression) or active 
metabolites. Next, if a drug is identified 
as a suitable candidate for MIPD, there is 
often more than one model or methodol-
ogy applicable. Pooling of available data 
(or even models) for the same drug-dis-
ease system and continuous updating 
with new incoming data allows to capture 
most realistic patient population scenar-
ios into a single model most appropriate 
for use in MIPD. In the future, as more 
frequent sampling (biosensors, wearables, 
point-of-care, or home-sampling devices) 
and advanced data-analysis methods (e.g., 
data assimilation or machine learning), 
become available for MIPD, better in-
formed and automated precision dosing 
could be achieved. Nevertheless, also in 
the future using big data and machine 
learning, the quality of the available data 
and the mechanistic understanding of the 
underlying processes are crucial. Despite 
readily developed MIPD tools emerging 
from academic/clinical research collabora-
tions, implementation into routine clinical 
care often fails. Translation of research 
findings into easy-to-use software tools is 
a crucial and challenging part of MIPD 
implementation, and expertise beyond 
quantitative pharmacology/pharmacom-
etrics is needed. Implementation research 
is required: there are various implementa-
tion strategies (training, education, adapt-
ability, flexibility, and changed clinician 
behavior) that need to be explored and 
evaluated to increase the uptake of MIPD 
into routine clinical practice. Following 
successful examples for MIPD tools5 
(and also other healthcare applications, 
Table S1), the establishment of guidelines 
and “best practices” should be fostered. 
Furthermore, in collaboration with medi-
cal societies, guidelines how to implement 
and successfully realize MIPD for specific 
drug-disease systems should be estab-
lished, as they are currently still lacking. 
Next to disease areas in which traditional 
TDM is well-established (e.g., infectious 
diseases, immunology, or transplantation 
medicine), new fields of application can be 
identified for MIPD.
PRACTICAL ASPECTS
Besides scientific questions, there are 
many practical challenges that need to be 
addressed for implementation of MIPD in 
patients’ drug therapy. First, the clinical 
infrastructure needs to be adapted to be 
ready for MIPD use at the bedside, but also 
for providing optimal ambulant or home-
based therapies using digital healthcare 
devices (e.g., wearable biosensors or point-
of-care devices) that allow patients to mea-
sure and report online individual drug/
biomarker concentrations. In the hospital, 
integration of available patient data might 
be difficult and time-consuming if they 
are still paper-based or multiple software 
tools are used for analysis, reporting, and 
communication of clinical samples. As 
electronic health record systems and point-
of-care devices become widely available, 
integration and interfaces with MIPD 
tools should be explored and expanded to 
further support and accelerate this digital 
trend. With today’s technical progress, this 
should soon no longer pose a challenge at 
least for high-income countries with good 
healthcare systems. Implementation of 
model-informed and optimal design ap-
proaches can further contribute to over-
come “classical” TDM problems, such as 
inappropriate timing, quality, and quan-
tity of PK or biomarker samples. Often 
highlighted major concerns in traditional 
TDM still comprise long bioanalytical 
turnaround times of samples (several 
hours to weeks), lack of standardization 
in workflows, and high instrumentation 
costs with complex sample preparation.8 
Raising awareness for benefits of optimal 
(often earlier and less) sampling time-
points, streamlining internal processes 
to shorten turnaround times, and intro-
ducing new concepts (e.g., point-of-care/
bedside analytics, biosensors/wearables, 
and home-monitoring systems9), using not 
only plasma, but also, for example, saliva, 
interstitial fluid, or capillary blood, will 




Nowadays, pharmacometric approaches 
are widely used within drug research and 
development and model-informed ap-
proaches (MID3) have been well accepted 
by regulatory agencies. Therefore, further 
exploiting their potential in postapproval 
phases, particularly to investigate popu-
lations that have not been well-studied 
within clinical development (e.g., preg-
nant women and obese patients) should be 
encouraged. For future drug development, 
it should be acknowledged that accepting 
more complex dosing will trigger higher 
response rates and fewer adverse drug re-
actions, thus facilitating drug approval 
and reimbursement.10 Recently, regulatory 
agencies and stakeholders in the healthcare 
systems have increasingly acknowledged 
the value and opportunities of MIPD and 
are open for input and discourse. The reg-
ulatory and reimbursement frameworks 
will need to adapt to, but at the same time 
also trigger changing trial designs, meth-
ods of analysis, and more flexible and com-
plex dosing recommendations. Of course, 
this does not apply for all investigational 
new drugs, but the right candidates should 
be identified early (e.g., based on projected 
low therapeutic indices or high treatment 
costs), and incorporation of precision dos-
ing should become a key consideration for 
approval, reimbursement, or therapeutic 
use.10 First initiatives with regard to pre-
cision dosing were kicked-off by regula-
tory agencies11 and the potential of MIPD 
should also be evaluated for other existing 
initiatives, such as the development of so-
called “companion diagnostics.”
CONCLUSIONS
Global awareness of the emerging need 
for precision dosing instead of the his-
toric “one-dose-fits-all-approach” for es-
tablished but also newly approved and 
investigational drugs is rising. New mobile 
healthcare devices gathering data from 
various sources become available, and the 
overall complexity of treatment decision 
making increases. Keeping pace in the era 
of digital health is only possible through 
advances in the field of MIPD. This in-
cludes user-friendly, evaluated, and scalable 
decision-support tools integrated in the 
clinical workflow, improved training for 
physicians and clinical pharmacists, estab-
lishment of “MIPD good practices,” and 
eventually initiatives investigating the ben-
efits of such MIPD tools over current prac-
tices. For the future of MIPD, we envision 
that MIPD will not only become an inte-
gral part of drug development, intrinsically 
motivated by initiatives within pharmaceu-
tical companies, and as a requirement by 
regulatory agencies, but also that through 
VOLUME 109 NUMBER 1 | January 2021 | www.cpt-journal.com36
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education, training, and widespread avail-
ability, its application goes beyond aca-
demic hospital centers in high-income 
countries and becomes readily available for 
more patients in need for optimized and 
individualized therapy. Multistakeholder 
collaborations ranging from drug develop-
ment to real-world and bedside application 
will be crucial to validate, implement, and 
demonstrate the value of MIPD.11
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